drugset
drugset / Trial / NCT01237340

Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study

NCT01237340 ↗

Phase 3 Terminated 59 enrolled EMD Serono
NaSingle-groupOpen-labelTreatment

Summary

To assess the immunogenicity of Saizen® solution for injection in adult subjects with documented Growth Hormone Deficiency (GHD).

Timeline

Start
2010-10
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic — Subcutaneous

Indications

No indication recorded.